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Between January 2000 and January 2010, 44 patients with relapsed AML after alloSCT were 3 treated. The patients were categorized according to their disease characteristics prior to alloSCT 4 as intermediate, poor-risk, or very poor-risk AML. Intermediate risk (int-risk) AML was defined 5 as <60 years old, white blood cell count (WBC) <100x10 9 /L at diagnosis, cytogenetically normal 6 (except for -X, -Y), and transplanted in first complete remission (CR1). Poor-risk AML was 7 defined as ≥60 years old and/or WBC >100x10 9 /L at diagnosis, and/or transplanted in second 8 complete remission (CR2) and/or not cytogenetically normal, favorable (t(15;17), t(8;21), or 9 inv(16)) or very poor (monosomal karyotype), and/or FLT3/ITD positive. In addition, acute 10 erythroid leukemia, acute megakaryocytic leukemia and mixed-phenotype acute leukemia were 11 also considered poor-risk. AML with a monosomal karyotype (MK) was defined as very poor-12 risk. Relapse after alloSCT was defined as an increase of blasts in the bone marrow (BM) to 5% or 39 more by morphology, and/or by the presence of more than 1% blasts in peripheral blood (PB), 40 and/or by the reappearance of molecular and/or cytogenetic markers. 41
Smoldering relapse was defined as a low percentage of blasts by morphology (<10% blasts in 42 BM and <5% blasts in PB) during a prolonged interval of at least 4 weeks evaluated by repeated 43 bone marrow aspiration. Other relapses were defined as high tumor burden relapse. Remission 44 status after DLI was assessed by bone marrow aspiration at 6 week, at 12 weeks after DLI, and at 45 every 3 months hereafter. Second relapse was defined as first relapse after DLI. 46
47

Treatment strategies for relapse 48
Patients with a poor performance status, defined as WHO performance status 3 or higher, and/or 49 with severe GvHD requiring systemic immuno-suppression at the time of relapse were unlikely 50 to benefit from an intensive DLI-based strategy and received palliative treatment only. 51
Patients with high tumor burden relapse received salvage re-induction therapy prior to infusion 52 of donor lymphocytes. In case of a response to re-induction therapy, defined as absence of 53 circulating leukemic blasts, unmanipulated DLI collected from the original donor was 54 administered at 3 weeks after start of re-induction therapy (during the neutropenic phase). In case 55 of a smoldering relapse, patients received DLI without prior cytoreductive treatment. 56 DLI-dosing depended on the time point after alloSCT, administration of pre-emptive DLI prior 57 to relapse and donor type. Median DLI-dose of patients transplanted with a (10 out of 10 HLA-58 matched) sibling donor was 5.0x10 6 CD3 + -cells/kg (range 1.0-100x10 6 CD3+cells/kg) and 59 2.5x10 6 CD3 + -cells/kg (range 1.5-7.8x10 6 CD3+cells/kg) for patients transplanted with an 60 unrelated donor (or a HLA-mismatched related donor), respectively. 61
The occurrence and impact of GvHD on outcome after relapse was evaluated in all patients 62 receiving DLI for relapse. Assessment and grading of GvHD was performed using modified 63 Glucksberg and Shulman criteria.(5, 6) . If no acute GvHD was observed within 3 weeks after 64 DLI, interferon-α was administered subcutaneously in a daily dose of 3 million units until GvHD 65 occurred. Escalating doses of DLI were administered in case of failure to develop acute GvHD at 66 3 months after start of treatment. Finally, grade 2-4 acute GvHD and severe chronic GvHD were 67 treated with prednisone 1-2 mg/kg/day. Ciclosporine or mofetil mycophenolate were added if 68 prednisone was administered for more than 2 weeks. 69
70
Statistical analysis 71
For different analyses, time was measured since relapse, initiation of re-induction therapy or 72 infusion of donor lymphocytes. Non-relapse mortality (NRM) was defined as death after DLI 73 while in continuous complete remission. Relapse-free survival was defined as survival after DLI 74 without second relapse. Probabilities of overall survival with associated 95% confidence 75 intervals (95% CI) were calculated by the Kaplan-Meier method; differences between groups 76 were compared using long-rank test. The cumulative incidence of acute GvHD after DLI was 77 calculated using R2.15.0 software, library 'cmprsk' (http://www.r-project.org/foundation). 78
To investigate the impact of a rapid immune response associated with acute GvHD on long-term 79 survival and disease recurrence after DLI, extended Cox regression models as proposed by 80
Andersen&Gill for overall survival, relapse-free survival and relapse incidence from starting 81 point DLI were constructed (see online supplementary method section for details). References of the supplementary method section 92 93
